A promising example of this synergistic approach comes from a recent phase II study, which combined 5-azacytidine with the thrombopoietin mimetic romiplostim in patients with myelodysplastic syndrome (MDS), showing positive outcomes [239]. Here, THPO is linked to myelodysplastic syndrome.